Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Takeda has entered into an exclusive licensing agreement with Keros Therapeutics for elritercept, a late-stage activin inhibitor designed to treat anemia in hematologic cancers. The agreement grants Takeda exclusive global rights outside mainland China, Hong Kong, and Macau. Elritercept targets myelodysplastic syndromes (MDS) and myelofibrosis (MF), and has received FDA Fast Track designation for MDS treatment. The drug has shown promising clinical activity in early studies. Takeda will pay $200 million upfront, plus potential milestone payments and royalties. Two Phase 2 trials are ongoing, with a Phase 3 RENEW trial for MDS patients starting soon.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences. The company's CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 10:30 a.m. ET, and the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 3:00 p.m. ET. Both presentations will be in a fireside chat format, with archived replays available on the Keros website for 90 days after each event.
Keros Therapeutics (NASDAQ: KROS) reported its Q3 2024 financial results and business highlights. The company announced completion of enrollment ahead of schedule in Phase 2 TROPOS trial of cibotercept. Financial results showed a net loss of $53.0 million compared to $39.4 million in Q3 2023. R&D expenses increased to $49.2 million from $34.1 million year-over-year. The company's cash position strengthened to $530.7 million, expected to fund operations into Q3 2027. Keros also appointed Yung H. Chyung as Chief Medical Officer effective November 1, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß signaling disorders, has announced its upcoming participation in the Guggenheim Healthcare Innovation Conference. Chair and CEO Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on November 13, 2024, at 3:30 p.m. Eastern time.
The presentation will be accessible via live audio webcast, with an archived version available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the presentation of three abstracts from its hematology program at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024. The presentations will showcase additional results from two ongoing Phase 2 clinical trials of elritercept (KER-050).
The trials focus on patients with lower-risk myelodysplastic syndrome (MDS) and myelofibrosis (MF). The presentations will highlight improvements in hematological parameters, quality of life, and clinical benefits of elritercept both as monotherapy and in combination with ruxolitinib. The abstracts were made public on the ASH website on November 5, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced an updated time for its presentation at the 2024 Cantor Global Healthcare Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation on Thursday, September 19, 2024, at 8:00 a.m. Eastern time.
Keros focuses on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The presentation will be available via live audio webcast, with an archived replay accessible on the company's investor relations website for up to 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the closure of screening for its TROPOS trial, a Phase 2 clinical study of cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH). The company expects to complete enrollment by the end of September and present topline data in Q2 2025, earlier than initially anticipated due to high demand and rapid enrollment. Keros, focused on developing therapies for disorders linked to dysfunctional TGF-ß family protein signaling, aims to bring a potentially differentiated treatment option to PAH patients. The company's leadership expressed gratitude to the investigators, research staff, and patients involved in this significant clinical research milestone.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming healthcare conferences in September 2024. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 4:05 p.m. ET
2. 2024 Wells Fargo Healthcare Conference on September 5 at 10:15 a.m. ET
3. 2024 Cantor Global Healthcare Conference on September 19 at 8:35 a.m. ET
All presentations will be in a fireside chat format. Archived replays will be available on the Keros website for up to 90 days after each event. Keros focuses on developing therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins.
Keros Therapeutics (Nasdaq: KROS) reported its Q2 2024 financial results, showing a net loss of $45.3 million, up from $37.5 million in Q2 2023. The increase was primarily due to expanded R&D efforts and investments in clinical and corporate goals. Research and development expenses rose to $40.5 million from $32.5 million year-over-year, while general and administrative expenses increased to $10.0 million from $8.8 million. Despite the losses, Keros' cash position strengthened to $405.9 million as of June 30, 2024, up from $331.1 million at the end of 2023. The company expects this cash reserve to fund operations into 2027. Keros highlighted positive regulatory and data updates for its elritercept (KER-050) program and strong enrollment in the Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
Keros Therapeutics (Nasdaq: KROS) announced leadership changes effective July 1, 2024. Dr. Jasbir Seehra, currently CEO, will become Chair of the Board, succeeding Dr. Carl Gordon, who will remain an active Board member. Jean-Jacques Bienaimé will take over as Lead Independent Director of the Board. Additionally, Christopher Rovaldi has been promoted to President, while retaining his role as Chief Operating Officer. These changes come as Keros prepares for its first Phase 3 clinical trial of elritercept (KER-050) for lower-risk myelodysplastic syndromes. Dr. Seehra and Dr. Gordon both expressed confidence in the new leadership structure to drive the company's strategic and operational priorities.